not used title
not used title
Cancer medicines cost nearly twice as much in hospital outpatient facilities than in physician offices in the commercial market, according to a new study from the Employee Benefit Research Institute Center for Research on Health Benefits Innovation. These cost differences were not driven by a difference in the severity of illness, but were driven by hospital pricing practices.
The study also found:
- Hospital outpatient facilities charged 1.3 to 4.3 times more than physician offices for cancer medicines.
- Employers and payers could save $9,766 per covered cancer patient in just one year if they paid physician office prices rather than hospital outpatient facilities prices for physician-administered cancer medicines.
- Employers could cut their medicine costs nearly in half without affecting quality of care if patients shifted toward physician offices, since nearly half of oncology therapy takes place in hospital outpatient facilities.
This study underscores just how much hospitals are driving health care spending in the United States by marking up medicines. A recent analysis found hospitals charge, on average, five times their cost for medicines, driving up cost sharing and premiums for patients across the country.
To learn more, read the study here and visit www.LetsTalkAboutCost.org.
Katie Koziara
Katie Koziara is Senior Director of public affairs at PhRMA focusing on the organization’s executive visibility work and media relations strategy. She previously ran the social media strategy for a D.C.-based non-profit working on federal management and leadership issues. Katie earned her B.A. in Public Policy from the University of Michigan’s Ford School and is currently earning her M.A. in Fiction Writing from Johns Hopkins University.
Katie Koziara
ICYMI: Hospital consolidation is driving up health care costs
August 27, 2026
New study: HPV vaccination helps prevent cervical cancer deaths
July 21, 2026
340B’s reality: A booming business for hospitals, pharmacies and corporate giants
June 25, 2026
America's cancer research progress is real and worth protecting
May 28, 2026
Ahead of ASCO: Cancer innovation is promising, but policy choices matter
May 26, 2026
A program off track: How 340B drives both hospital consolidation and system gaming
April 27, 2026
Washington Post Editorial Board says 340B has become “corporate welfare”
April 27, 2026
Hospitals drive nearly 80% of the U.S. health spending gap
March 25, 2026
Congress should look under the hood of 340B, hospitals don't want them to
March 19, 2026
340B hospitals buy low and sell high, a new analysis shows
March 12, 2026
New report from Minnesota: 340B is generating billions for big hospitals
March 9, 2026
Advancing patient care: A look at new medicines approved in 2025
January 30, 2026
CAREs 2025: Supporting community-based solutions that improve access to medicines
January 22, 2026
New analysis finds 340B hospitals push patients toward costly care to boost profits
January 21, 2026
Price setting policies put cancer gains in jeopardy
January 16, 2026
Latest analysis from Ohio exposes growing abuses of the 340B markup program
July 7, 2025
Improved treatments continue to lead to declining cancer mortality rates in the U.S.
February 25, 2025
Guest Perspective: Prioritize Innovative Care
February 11, 2025
Preventing and fighting disease: A look at the biopharmaceutical progress made for patients in 2024
February 3, 2025
Post-approval R&D is critical for fighting cancer. The IRA makes it more difficult.
November 13, 2024
The importance of partnership: A conversation with Takeda
October 10, 2024
The future of oncology R&D lies in policymakers’ hands
July 8, 2024
Showcasing the promise of biopharma at ASCO 2024
June 28, 2024
Critics repeat same, misleading narrative on potential “costs” of new medicines
May 7, 2024
Championing cancer equity: Our drive for healthier AANHPI communities
May 1, 2024
Insurance data: PBM reform has no material impact on premiums
April 24, 2024
What recent rhetoric on the cost of diabetes and anti-obesity medicines gets wrong
April 9, 2024
3 Takeaways from POLITICO’s Health Care Summit
April 3, 2024
The impact of innovative medicines: A caregiver's perspective
March 26, 2024
PhRMA awards $250,000 to community-based projects to improve equitable cancer outcomes
February 9, 2024
Setting the Record Straight: Comparing U.S. drug prices to those in foreign countries hurts patients
February 7, 2024
Three things to know about antibody drug conjugates
February 2, 2024
When it comes to the future of innovation, the ball is in policymakers’ court
January 22, 2024
The IRA’s pill penalty threatens the future of oncology R&D
November 16, 2023
New Report: 1,600 cancer treatments and vaccines in clinical development
November 9, 2023
R&D leaders to Biden Administration: Your policies are undermining the Cancer Moonshot
October 18, 2023
By the Numbers: 340B continues to climb in profits, dwindle with patient support
September 13, 2023
Watch: New video series spotlights advances in biopharmaceutical science
August 24, 2023
AARP’s latest misleading report
August 11, 2023
New report: Hospitals mark up medicine prices 500%
August 2, 2023
read more
August 2, 2023
Key considerations as Congress works towards PAHPA reauthorization
July 12, 2023
Between hope and despair: Improving cancer outcomes
July 11, 2023
New report shows high-impact R&D happens after cancer medicines are first approved
July 10, 2023
New report shows how the Inflation Reduction Act stifles innovation for small molecule medicines
June 22, 2023
ASCO 2023: Protecting our progress in the fight against cancer
June 15, 2023
Highlights from ASCO 2023
June 8, 2023
Insulin: Key Facts on Access & Affordability
May 10, 2023
4 key facts on medicine prices and spending
May 9, 2023
Three facts about health care spending
April 25, 2023
Nonprofit hospitals fall short on community benefit, studies show
April 24, 2023
IRA Impacts: Cancer treatment research and development
March 23, 2023
Why Congress should prioritize fixing the 340B program
March 2, 2023
What they are saying: Nonprofit hospitals are gaming the system at the expense of patients
February 21, 2023
State policymakers can protect American innovation and help Americans live longer, healthier lives
February 9, 2023
ICYMI: Cancer death rate continues to decline due to treatment advances
January 25, 2023
Novel medicines approved in 2022 offer increased treatment options for patients
January 23, 2023
ICYMI: PhRMA kicks off the year at the 2023 J.P. Morgan Health Care Conference
January 19, 2023
Study finds hepatitis C cure saved Medicaid $15 billion
January 5, 2023
340B program continues to drive shift in care to more expensive hospital settings
December 15, 2022
Stories from the lab: Researchers discuss innovative treatments for cancers of the blood
December 1, 2022
New data show how insurers and middlemen shift Rx costs onto patients
November 16, 2022
ICYMI: PhRMA COO Lori Reilly Esq. speaks with Jacob Van Naarden about the future of cancer research
November 8, 2022
Protecting treatment advances for breast cancer
October 31, 2022
Busting 3 Myths About Copay Coupons
October 5, 2022
Making coupons count for patients at the pharmacy counter
August 25, 2022
By the Numbers: Patients lose when the government sets prices
July 8, 2022
Prescription drug prices are not fueling inflation
July 6, 2022
Key takeaways from ASCO's annual meeting
June 10, 2022
PhRMA warns of the growing influence of middlemen over patient access and out-of-pocket costs for patients
May 31, 2022
Report finds PBMs are increasingly restricting patient access to medicines
May 25, 2022
ICYMI: First pediatric patient to receive CAR-T cell therapy celebrates 10 years of being cancer-free
May 25, 2022
Report: More than 500 medicines in development to treat disorders of the blood
May 18, 2022
ICYMI: PhRMA CEO Stephen J. Ubl spotlights lessons learned during COVID-19
May 13, 2022
Annual projections from NHE compared to actual health care spending
May 5, 2022
What’s really happening when it comes to prescription drug costs
April 27, 2022
Analysis: States can help patients save nearly $1,000 annually on their medicines
April 21, 2022
New analysis confirms hospitals markup prices for oncology therapies
April 21, 2022
How standardized plans can improve patients’ access to medicines
April 18, 2022
Correcting the record: Putting medicine costs and spending in context
March 24, 2022
Sharing rebates can save Americans with diabetes 500 each year and improve adherence
March 16, 2022
Guest Post: If we truly want to cure complex diseases, politicians should reject price setting
March 14, 2022
Veterans Affairs 101: Three charts show how the VA system differs from Medicare
March 11, 2022
If drug prices are growing below the rate of inflation, why are patients still feeling the sting at the pharmacy?
March 8, 2022
4 things to know about biopharmaceutical efforts to fight cancer
February 24, 2022
Government price setting leaves behind families counting on new medicines
February 23, 2022
340B 101: Three charts show the program maximizes hospitals’ bottom line with little consideration for patients
February 8, 2022
Research and development continues long after a medicine is initially approved
February 1, 2022
New poll of all 50 states and 435 Congressional Districts shows perils of so-called Medicare “negotiation”
January 25, 2022
CBO reaffirms our innovation ecosystem leads to improved lives, long-term savings
January 21, 2022
New data show continued decline in death rates for cancer patients related to treatment advances
January 20, 2022
New study finds more than half of brand medicine spending goes to the supply chain and others
January 7, 2022
New NHE data show the true picture of health care spending
December 22, 2021
3 things to know about the importance of post-approval research and development
December 6, 2021
Guest post: Congress should not put future innovation at risk
November 29, 2021
What is missing in the current drug pricing plan
November 23, 2021
ICYMI: PhRMA CEO speaks at STAT Summit about government price setting
November 19, 2021
In the current health care debate, Congress has lost sight of what matters to U.S. voters
November 15, 2021
CMS finds medication adherence saved Medicare up to 46.6B in avoided health care costs between 2013 and 2018
October 19, 2021
ICYMI: New study confirms policies like H.R. 3 could significantly reduce drug development
October 18, 2021
New poll shows Americans reject Medicare negotiation once they learn more about the policy
October 15, 2021
To drive up profits, hospitals continue unnecessary medicine mark-ups, burdening patients, employers and health care system
October 14, 2021
What is Kaiser Family Foundation up to?
October 12, 2021
Recognizing National Immunization Awareness Month
August 31, 2021
Recognizing Hepatitis R&D on World Hepatitis Day
July 28, 2021
340B hospitals among those that provide lowest levels of community benefit across the country
July 27, 2021
New reports shed light on key facts about medicines and affordability
June 8, 2021
How strengthening the biosimilar marketplace benefits patients
May 18, 2021
New report demonstrates development of new medicines relies on private sector expertise and investment
May 10, 2021
New data from insurers show detriments of copay accumulator adjustment programs
April 28, 2021
West Virginia becomes the first state to lower patient costs by sharing the savings
April 20, 2021
Getting the 340B program back on track in 2021
March 10, 2021
Nearly 40% of commercially insured patients face half their annual out-of-pocket expenses from just one health care encounter
March 2, 2021
Top five issues voters want addressed in the administration’s first 100 days
February 18, 2021
Action needed to preserve the six protected classes
February 3, 2021
Insurers shift medicine costs to patients with severe chronic illnesses
February 1, 2021
The new Administration should reconsider a recent HHS rule that could negatively impact patient access and affordability
January 27, 2021
New insulin report highlights how incentives benefit middlemen, harm patients
January 22, 2021
ICYMI: Cancer death rate continues decline due to advances in treatment
January 19, 2021
New data show retail medicine prices fell in 2019
January 13, 2021
Correcting the record: Biopharmaceutical companies remain committed to the 340B program and helping patients
December 17, 2020
Report: More than 1,300 medicines and vaccines in development to help fight cancer
December 15, 2020
Fact Check: How hospitals continue to drive health care spending
December 3, 2020
Accumulator adjustment programs lead to surprise out-of-pocket costs and nonadherence, analysis finds
November 19, 2020
340B hospitals and for-profit pharmacies generating significant revenue from program meant to help needy patients
October 23, 2020
Study finds biopharmaceutical innovation is responsible for 35% of the increase in life expectancy from 1990 to 2015
October 21, 2020
Survey found insurance premiums grew faster than inflation in 2020
October 20, 2020
Study finds middlemen excluded nearly 850 medicines from formularies this year
September 17, 2020
Manufacturer cost-sharing assistance programs can save chronically ill patients hundreds to thousands of dollars annually
August 19, 2020
Commercial health plans have increased patients’ out-of-pocket costs by over 50% in some therapeutic areas
August 12, 2020
Commercial health plans transition from copays to coinsurance and deductibles has increased patient out-of-pocket costs
August 6, 2020
Four things to know about the IQVIA “Medicine Spending and Affordability in the U.S.” report
August 5, 2020
New data show commercially insured patients face increasingly high cost sharing for brand medicines
July 30, 2020
Payers subject 80% of new RA and MS patients to utilization management restrictions
July 22, 2020
New report explores setbacks that bring future cancer success stories
July 16, 2020
Study finds the pharmaceutical industry retains a smaller share of revenue than research-intensive industries
July 14, 2020
Guest Post: Takeda seeks ‘new normal’ for cancer research during the COVID-19 pandemic
June 24, 2020
ICYMI: Pharmacy benefit managers increasingly exclude medicines from formularies, restricting patient access
June 1, 2020
New rule makes it harder for patients to lower their out-of-pocket costs
May 20, 2020
ICYMI: Patients saved nearly $800,000 out of pocket through innovative contracting arrangements
April 20, 2020
Retail medicine spending to remain stable share of overall health care spending through next decade
April 16, 2020
PhRMA comments on HHS proposed rule on manufacturer cost-sharing assistance and accumulator adjustment programs
March 3, 2020
Addressing barriers that inhibit value-based contracts
February 21, 2020
Fact Check: HCCI analysis overstates medicine spending and prices
February 19, 2020
New GAO report: Some hospitals participating in 340B may not be eligible for the program
January 14, 2020
Nearly 50% of brand medicine spending goes to the supply chain and others
January 9, 2020
New NHE data: Medicine prices declined, and hospitals were biggest driver of health care spending in 2018
December 6, 2019
More evidence that medicine prices are growing at slowest rate in decades
October 4, 2019
The truth about the marketing and promotion of medicines
October 3, 2019
Survey shows out-of-pocket costs top health care concern for voters
October 2, 2019
Four reasons why the radical Pelosi Plan is the wrong approach
September 24, 2019
Hospitals make 9 times more than physicians’ offices on provider-administered medicines
September 10, 2019
340B Spotlight: How for-profit middlemen are taking advantage of a program meant to support nonprofit entities and patients
August 20, 2019
Three things to know about the Part D GAO report
August 16, 2019
Setting the record straight on international reference pricing
July 16, 2019
Four states adopt first-in-the-nation laws to protect patients from surprise insurer practices
July 15, 2019
New Let’s Talk About Cost TV ad asks: Why aren’t patients sharing in savings at the pharmacy counter?
July 9, 2019
Study finds hospitals continue to mark up medicines up to 500% of their cost
July 9, 2019
Three reasons why the latest Rx Savings Solutions analysis is misleading
July 2, 2019
"If Washington isn’t careful, we might leave innovation behind"
June 24, 2019
How the rebate rule would help reduce patients’ out-of-pocket costs
June 3, 2019
Fresh data show, yet again, 340B is growing while charity care dwindles at many 340B hospitals
May 16, 2019
Ask About Adherence: OIG proposed rule to reform the rebate system could improve adherence
May 15, 2019
New study finds hospitals continue to push patients to costlier outpatient settings
May 13, 2019
4 Things to know about the IQVIA “Medicine Use and Spending” report
May 9, 2019
Meet MAT: 5 things to know about PhRMA’s new “Medicine Assistance Tool”
May 9, 2019
Six policy solutions to help patients afford their insulin
April 9, 2019
PhRMA comments on OIG proposed rule to reform the rebate system
April 8, 2019
340B continues to drive shift in site of care for physician-administered medicines to more expensive hospital settings
April 5, 2019
Five key facts about the market for insulins
April 1, 2019
OIG proposed rule could help strengthen the Part D market
March 28, 2019
Rebate rule would help ensure seniors with diabetes don’t pay more for their medicine than their insurer
March 25, 2019
The PBM story you haven’t heard: Hidden fees quadrupled in two years
March 20, 2019
OptumRX: Sharing rebates with patients is “worth it”
March 18, 2019
New data show how sharing negotiated discounts could save certain patients hundreds of dollars at the pharmacy counter
February 25, 2019
What you need to know about the new NHE health spending projections
February 22, 2019
New study shows why insurers should share rebates with Medicare Part D beneficiaries on a mandatory basis
February 14, 2019
New IQVIA data show medicine prices grew just 1.5 percent in 2018
January 29, 2019
Health Affairs study misses the mark on medicine costs
January 28, 2019
New government data show medicine price growth continues to decline
January 18, 2019
10 things you should know about medicine spending and costs
January 2, 2019
New study finds hospitals prescribe more medicines, and more expensive medicines, after joining 340B program
December 18, 2018
Six key facts about the market for insulins
December 17, 2018
Americans want to know more than just the list price of a medicine—and we’re answering their call
October 15, 2018
What they are saying: PhRMA member executives on industry’s new approach to DTC television advertising
October 15, 2018
Coupons allow patients to remain on medicines in spite of high cost sharing and deductibles
October 4, 2018
Experts agree: the Bipartisan Budget Act changes to Medicare Part D jeopardize the program
September 24, 2018
Saving kids and dogs from shared cancers
September 17, 2018
What if a couple of small fixes could protect seniors in the donut hole and save them money on out-of-pocket costs?
September 13, 2018
New study finds some hospitals mark up medicine prices at least 700 percent
September 5, 2018
69 percent of patients abandon medicines when cost sharing is more than $250
August 23, 2018
New analysis finds 340B medicine sales hit record high in 2017 and continue to grow as a share of total drug spending
August 20, 2018
New analysis in Health Affairs reinforces one-third of medicine list price rebated back to supply chain
August 13, 2018
PhRMA submission to HHS on blueprint to lower drug prices and reduce out-of-pocket costs
July 16, 2018
GAO again recommends improvements to 340B program
July 11, 2018
New data show patients’ out-of-pocket costs are rising faster than their insurers’ costs
July 9, 2018
Pass-through rebates do not violate non-interference clause but they do increase savings for seniors
July 2, 2018